Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine announced on October 31, 2016 that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a ground-breaking initiative that completes a seamless, fully funded, and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases. Bridge Medicines builds upon the work of the independent, non-profit Tri-Institutional Therapeutics Discovery Institute, known as Tri-I TDI. Scientists at the Tri-I TDI, which launched in 2013, are working in the laboratory on approximately 50 early-stage drug discovery projects — spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases — with the hope that they might be translated into future treatments for patients. Research projects accepted into the Tri-I TDI will now be able to graduate to Bridge Medicines, where they will be given financial, operational, and managerial support to move seamlessly from a validating, proof-of-concept study to an in-human clinical trial. Typically, investigators behind promising early-stage discoveries must search for a biopharmaceutical company to purchase or license their intellectual property, or find a funding opportunity to support additional research. This process can be time-consuming and may shift investigators’ focus away from science, slowing down and in some cases ending the development path. “The launch of Bridge Medicines is a truly exciting development in New York’s biotechnology space,” said Dr.
Login Or Register To Read Full Story